india tirzepatide Eli Lilly could launch obesity drug in next year, CEO says India one step closer to

This represents the highest weight loss ever recorded in a Phase 3 obesity trial, surpassing even the company's own dual agonist tirzepatide (Mounjaro/Zepbound), which achieved 22.5% in its pivotal studies

Click PLACE ORDER to proceed to the next window where you can input your debit card information

Research suggests this dual action may be why tirzepatide can be more effective than semaglutide for weight loss and blood sugar control

Contraindications include personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, and severe gallbladder disease

It remains unavailable outside of clinical trials, with FDA approval not expected until late 2026 or early 2027